While early CD8 T cell chimerism was around 0.25% 18 h after ATCT, therapeutic T cells expanded ~80‐fold within 3 weeks (Fig 4D) and persisted long‐term at high levels to protect from HLH relapses. This evidence concerns the gene CD8A and hemophagocytic syndrome.